Navigation Links
S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
Date:4/14/2011

SINGAPORE, April 14, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that it has dosed the first 10 patients in a Phase 2 clinical trial of its novel JAK2 inhibitor SB1518 in the U.S. and Canada for the treatment of advanced lymphoid malignancies.

This multi-center, open-label, study is designed to primarily evaluate the efficacy and safety of SB1518 in patients with advanced lymphoid malignancies in five sites including M.D. Anderson, Rochester University, Cornell University, University of Nebraska, and British Columbia Cancer Center. Secondary objectives include duration of response and progression-free survival.  Based on the safety and clinical benefit data from a Phase 1 trial, patients are receiving a 400mg dose of SB1518 orally daily. The trial will enroll up to 87 lymphoma patients and will determine the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies such as Hodgkin's Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma.

Previously presented lymphoma data at the 52nd ASH Annual Meeting and Exposition demonstrated SB1518's clinical benefits in a Phase 1 dose ranging study. Three patients showed partial response and 15 patients maintained stable disease states.  The majority of the responses were sustained for greater than two months.

"The development of SB1518 in a second indication is a significant milestone in the clinical advancement of our lead JAK2 inhibitor," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "The initiation of this Phase 2 trial demonstrates our commitment in advancing this best-in-class compound and addressing the unmet medical need for an effective treatment of lymphoma.  This trial closely follows our recent announcement of data from Phase 1/2 studies for SB1518 indicating its clinical efficacy and good tolerability for the treatment of patients with symptomatic myelofibrosis and enlarged spleens."

S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. have a dev
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. S*BIO Completes US$26 Million Equity Financing
2. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
3. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
4. S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
5. S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
6. S*BIO Announces US$5 Million Investment by Mitsui Ventures
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
9. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
10. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
11. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Marktech Optoelectronics has introduced the MTE280xxx ... in the 280 nm wavelength range. This series joins ... from 280nm to 405nm. These new devices are suitable ... as curing. Mark Campito, Marktech’s CEO states that “what ... manufacturers is that we offer it in one of ...
(Date:9/22/2014)... who were treated with a statin in the hospital ... likely to survive than those who were not, according ... . This study was conducted by the same researchers ... can improve survival in victims of ischemic stroke., Ischemic ... a blood vessel that blocks blood from reaching areas ...
(Date:9/22/2014)... job it is to stop bleeding, are very simple. ... "feel" the physical environment around them, researchers at Emory ... surfaces with greater stiffness by increasing their stickiness, the ... other components of the clotting system, the researchers found. ... for, in that they are able to sense the ...
(Date:9/22/2014)... D.C. (PRWEB) September 22, 2014 ... Georgetown President John DeGioia on Friday renewed their ... for an additional five years to expand the ... biosecurity, nonproliferation and global climate, energy and environmental ... of an MOU originally signed in December 2009 ...
Breaking Biology Technology:Marktech Introduces its New Line of Deep UV Emitters 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Platelets modulate clotting behavior by 'feeling' their surroundings 2Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2
... and PHILADELPHIA, July 4 ,Shire Limited (LSE:SHP, NASDAQ: SHPGY), ... earnings on,Thursday 31 July 2008, Results press ... BST / 07:00 EDT Investor meeting and conference ... Investor & Analyst meeting and conference call:, Angus ...
... Research Group has,released results from aboratory testing ... at Oregon State University which,demonstrated the Eniva ... for human cells. This third party testing ... effort to further identify,mechanisms by which the ...
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) today announced that ... its cash burn rate. As previously,announced, the Company ... acquisitions and mergers. In conjunction with this,process, the ... its VP,series of drugs, and has determined that ...
Cached Biology Technology:Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008 2Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties 2Vasogen Provides Corporate Update 2
(Date:9/23/2014)... DNA fragments called "jumping genes" that insert themselves into ... that phenomenon can result in age-related diseases such as ... report that the "jumping genes" in mice become active ... keeping them in check in order to take on ... in Nature Communications , Professor of Biology Vera ...
(Date:9/22/2014)... that after a long stay in the Intensive Care ... remain behind in patients, intestines. The team tested these ... when provoked by conditions that mimic the body,s stress ... mBio , the online open-access journal of the American ... treatment of ICU patients who can develop a life-threatening ...
(Date:9/22/2014)... September 23, 2014 A new American Cancer ... Nutrition Assistance Program (SNAP), previously known as the ... compared with income eligible non-participants. The authors say ... aimed at enhancing the dietary quality of SNAP ... low-income individuals and households with the resources to ...
Breaking Biology News(10 mins):A multi-function protein is key to stopping genomic parasites from 'jumping' 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Federal food program puts food on the table, but dietary quality could be improved 2
... Hidenori Ichijo and Hideki Nishitoh (The University of Tokyo) ... genetics of ALS. Amyotrophic lateral sclerosis (ALS), also ... fatal neurological disease involving the degeneration and death of ... the most common neuromuscular diseases worldwide, affecting as roughly ...
... sturgeons, more caviar will be exported from Caspian Sea ... of unacceptably permissive new trade quotas announced Thursday by ... Most sturgeon species are endangered and some, like beluga ... damage this ancient fish,s chance of recovery and survival, ...
... New research* shows that while engineered nanomaterials can ... food chain from single celled organisms to higher ... and there was no evidence of the nanomaterials ... results observed by researchers from the National Institute ...
Cached Biology News:New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 2New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 3New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 4Research measures movement of nanomaterials in simple model food chain 2
Request Info...
These macrocarriers are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 macrocarriers....
... 211 ] affinity isolated antibody aqueous solution ... (without Mg 2+ and Ca 2+ ), ... protease free) and 0.05% sodium azide. a synthetic ... Hck that contains tyrosine 207 and serine 209 ...
High voltage electrophoresis power supply...
Biology Products: